1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
Escoubas, P.
Bernard, C.
Lazdunski, M.
Darbon, H.
http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic
C6 H15 N4 O2 1
175.209
y
ARGININE
L-peptide linking
C4 H8 N2 O3
132.118
y
ASPARAGINE
L-peptide linking
C4 H7 N O4
133.103
y
ASPARTIC ACID
L-peptide linking
C3 H7 N O2 S
121.158
y
CYSTEINE
L-peptide linking
C5 H9 N O4
147.129
y
GLUTAMIC ACID
L-peptide linking
C2 H5 N O2
75.067
y
GLYCINE
peptide linking
C6 H10 N3 O2 1
156.162
y
HISTIDINE
L-peptide linking
C6 H13 N O2
131.173
y
ISOLEUCINE
L-peptide linking
C6 H13 N O2
131.173
y
LEUCINE
L-peptide linking
C6 H15 N2 O2 1
147.195
y
LYSINE
L-peptide linking
C9 H11 N O2
165.189
y
PHENYLALANINE
L-peptide linking
C5 H9 N O2
115.130
y
PROLINE
L-peptide linking
C3 H7 N O3
105.093
y
SERINE
L-peptide linking
C4 H9 N O3
119.119
y
THREONINE
L-peptide linking
C11 H12 N2 O2
204.225
y
TRYPTOPHAN
L-peptide linking
C5 H11 N O2
117.146
y
VALINE
L-peptide linking
US
Protein Sci.
PRCIEI
0795
0961-8368
12
1332
1343
10.1110/ps.0307003
12824480
Recombinant production and solution structure of PcTx1, the specific peptide inhibitor of ASIC1a proton-gated cation channels
2003
10.2210/pdb1lmm/pdb
pdb_00001lmm
1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
1
SINGLE WAVELENGTH
M
1
1.0
4705.513
Psalmotoxin 1
1
man
polymer
PcTx1
no
no
EDCIPKWKGCVNRHGDCCEGLECWKRRRSFEVCVPKTPKT
EDCIPKWKGCVNRHGDCCEGLECWKRRRSFEVCVPKTPKT
A
polypeptide(L)
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
Trinidad chevron tarantula
Psalmopoeus
Escherichia
sample
179874
Psalmopoeus cambridgei
562
Escherichia coli
database_2
pdbx_nmr_software
pdbx_struct_assembly
pdbx_struct_oper_list
repository
Initial release
Version format compliance
Version format compliance
Data collection
Database references
Derived calculations
1
0
2003-11-25
1
1
2008-04-28
1
2
2011-07-13
1
3
2022-02-23
_database_2.pdbx_DOI
_database_2.pdbx_database_accession
_pdbx_nmr_software.name
RCSB
Y
RCSB
2002-05-02
REL
structures with the lowest energy
30
20
DQF-COSY
2D TOCSY
2D NOESY
DQF-COSY
2D TOCSY
2D NOESY
3.6
ambient
283
K
3.6
ambient
300
K
distance geometry, simulated annealing
2.9 mm
collection
XwinNMR
2.6
processing
XwinNMR
2.6
Bartels
data analysis
XEASY
1.3
Gnthert
structure solution
DIANA
2.8
Brunger
refinement
CNS
1.1
500
Bruker
DRX
GLU
1
n
1
GLU
1
A
ASP
2
n
2
ASP
2
A
CYS
3
n
3
CYS
3
A
ILE
4
n
4
ILE
4
A
PRO
5
n
5
PRO
5
A
LYS
6
n
6
LYS
6
A
TRP
7
n
7
TRP
7
A
LYS
8
n
8
LYS
8
A
GLY
9
n
9
GLY
9
A
CYS
10
n
10
CYS
10
A
VAL
11
n
11
VAL
11
A
ASN
12
n
12
ASN
12
A
ARG
13
n
13
ARG
13
A
HIS
14
n
14
HIS
14
A
GLY
15
n
15
GLY
15
A
ASP
16
n
16
ASP
16
A
CYS
17
n
17
CYS
17
A
CYS
18
n
18
CYS
18
A
GLU
19
n
19
GLU
19
A
GLY
20
n
20
GLY
20
A
LEU
21
n
21
LEU
21
A
GLU
22
n
22
GLU
22
A
CYS
23
n
23
CYS
23
A
TRP
24
n
24
TRP
24
A
LYS
25
n
25
LYS
25
A
ARG
26
n
26
ARG
26
A
ARG
27
n
27
ARG
27
A
ARG
28
n
28
ARG
28
A
SER
29
n
29
SER
29
A
PHE
30
n
30
PHE
30
A
GLU
31
n
31
GLU
31
A
VAL
32
n
32
VAL
32
A
CYS
33
n
33
CYS
33
A
VAL
34
n
34
VAL
34
A
PRO
35
n
35
PRO
35
A
LYS
36
n
36
LYS
36
A
THR
37
n
37
THR
37
A
PRO
38
n
38
PRO
38
A
LYS
39
n
39
LYS
39
A
THR
40
n
40
THR
40
A
author_defined_assembly
1
monomeric
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
1_555
x,y,z
identity operation
0.0000000000
0.0000000000
0.0000000000
A
N
GLU
22
A
N
GLU
22
A
O
VAL
34
A
O
VAL
34
1
-3.38
0.50
120.30
116.92
A
A
A
NE
CZ
NH2
ARG
ARG
ARG
13
13
13
N
2
-3.35
0.50
120.30
116.95
A
A
A
NE
CZ
NH2
ARG
ARG
ARG
13
13
13
N
6
-3.10
0.50
120.30
117.20
A
A
A
NE
CZ
NH2
ARG
ARG
ARG
13
13
13
N
10
-3.34
0.50
120.30
116.96
A
A
A
NE
CZ
NH2
ARG
ARG
ARG
13
13
13
N
12
-3.58
0.50
120.30
116.72
A
A
A
NE
CZ
NH2
ARG
ARG
ARG
13
13
13
N
13
-3.25
0.50
120.30
117.05
A
A
A
NE
CZ
NH2
ARG
ARG
ARG
13
13
13
N
19
-3.41
0.50
120.30
116.89
A
A
A
NE
CZ
NH2
ARG
ARG
ARG
13
13
13
N
1
A
VAL
11
-41.19
159.64
1
A
ASN
12
75.20
83.36
1
A
ARG
13
83.21
-16.71
1
A
HIS
14
51.61
87.10
1
A
CYS
17
-42.91
150.45
1
A
CYS
18
-70.13
-96.35
1
A
GLU
19
-61.89
-154.53
1
A
ARG
26
-74.64
-159.69
1
A
SER
29
-57.53
177.53
1
A
PHE
30
-66.04
-167.14
1
A
LYS
36
-54.15
-78.28
1
A
PRO
38
-92.67
-88.93
1
A
LYS
39
-70.27
-78.60
2
A
VAL
11
-53.58
86.10
2
A
ASN
12
175.41
81.11
2
A
HIS
14
45.98
71.19
2
A
CYS
17
-47.25
151.83
2
A
CYS
18
-67.81
-97.22
2
A
GLU
19
-62.87
-155.03
2
A
ARG
28
-100.78
-68.11
2
A
PHE
30
-70.25
-152.67
2
A
LYS
36
-48.73
-76.19
2
A
PRO
38
-65.23
71.42
3
A
ASP
2
-60.34
86.27
3
A
LYS
6
-59.88
-170.18
3
A
ASN
12
59.50
18.92
3
A
CYS
18
-69.96
-93.11
3
A
GLU
19
-61.41
-159.60
3
A
SER
29
-58.88
171.25
3
A
PHE
30
-68.60
-157.39
4
A
VAL
11
-58.97
82.02
4
A
ASN
12
177.46
75.16
4
A
HIS
14
48.28
84.10
4
A
CYS
18
-55.35
-94.71
4
A
GLU
19
-66.64
-154.94
4
A
ARG
27
-70.49
-73.05
4
A
PHE
30
-63.06
-147.11
4
A
PRO
38
-75.38
-70.14
5
A
CYS
3
-70.16
-95.47
5
A
VAL
11
-60.47
82.35
5
A
ASN
12
177.59
81.50
5
A
HIS
14
46.23
83.63
5
A
CYS
18
-70.24
-88.57
5
A
GLU
19
-67.88
66.47
5
A
ARG
28
-95.98
-82.15
5
A
PHE
30
-70.25
-153.66
5
A
VAL
34
-170.33
138.16
5
A
LYS
36
-48.15
-89.51
5
A
LYS
39
-63.61
82.65
6
A
VAL
11
-67.60
70.26
6
A
ASN
12
-177.22
-70.51
6
A
HIS
14
53.63
92.41
6
A
CYS
18
-70.40
-83.31
6
A
GLU
19
-63.79
-153.29
6
A
PHE
30
-60.48
-158.15
6
A
PRO
38
-80.12
-75.35
7
A
CYS
3
-62.35
-176.66
7
A
ASN
12
-177.32
-54.38
7
A
HIS
14
52.26
84.88
7
A
CYS
17
-51.58
172.63
7
A
CYS
18
-64.62
-96.70
7
A
GLU
19
-65.78
-164.89
7
A
ARG
26
-116.53
-168.18
7
A
ARG
27
-70.15
-76.16
7
A
PHE
30
-69.94
-82.10
7
A
THR
37
-47.10
104.94
7
A
PRO
38
-63.57
-157.03
8
A
VAL
11
-59.05
87.84
8
A
ASN
12
-176.84
78.82
8
A
HIS
14
44.24
83.04
8
A
CYS
17
-57.76
179.63
8
A
CYS
18
-68.99
-95.12
8
A
GLU
19
-63.91
-155.80
8
A
ARG
28
-92.51
-75.94
8
A
SER
29
-68.13
-176.11
8
A
PHE
30
-70.10
-149.02
8
A
VAL
32
-170.11
144.81
8
A
LYS
36
-64.66
-131.54
9
A
CYS
3
-59.20
177.11
9
A
VAL
11
-57.42
85.51
9
A
ASN
12
179.76
80.91
9
A
CYS
18
-70.03
-105.76
9
A
GLU
19
-60.23
-161.47
9
A
ARG
27
-70.02
-79.70
9
A
PHE
30
-70.04
-156.42
10
A
ASP
2
-63.50
82.31
10
A
LYS
6
-96.02
30.81
10
A
TRP
7
-148.21
29.30
10
A
ASN
12
172.96
-36.88
10
A
CYS
18
-60.31
-85.64
10
A
GLU
19
-70.34
-161.89
10
A
ARG
28
-70.32
-80.96
10
A
PHE
30
-57.59
-80.03
10
A
VAL
32
-170.28
142.21
10
A
VAL
34
-173.18
137.55
10
A
LYS
36
-60.34
-78.94
10
A
PRO
38
-88.16
-77.87
11
A
ASP
2
-67.17
74.13
11
A
PRO
5
-53.80
171.78
11
A
TRP
7
-147.99
29.32
11
A
ASN
12
68.88
84.53
11
A
ARG
13
76.39
82.32
11
A
HIS
14
-67.48
49.74
11
A
CYS
17
-69.73
-159.81
11
A
CYS
18
-70.31
-105.29
11
A
GLU
19
-70.43
-160.46
11
A
ARG
28
-101.57
-70.99
11
A
PHE
30
-69.96
-155.64
11
A
LYS
39
-53.66
-177.63
12
A
ASP
2
-65.86
77.55
12
A
CYS
3
-59.43
172.67
12
A
ASN
12
-153.89
-86.87
12
A
HIS
14
53.81
79.22
12
A
CYS
18
-56.98
-103.36
12
A
GLU
19
-63.97
-157.19
12
A
ARG
26
-78.99
-168.45
12
A
ARG
28
-133.71
-42.30
12
A
SER
29
-59.07
173.03
12
A
PHE
30
-61.95
-167.45
12
A
LYS
36
-70.14
-100.22
12
A
PRO
38
-84.20
42.34
13
A
VAL
11
-49.79
89.50
13
A
ASN
12
173.61
84.49
13
A
ARG
13
46.11
27.71
13
A
CYS
17
-57.10
177.23
13
A
CYS
18
-70.17
-108.24
13
A
GLU
19
-63.66
-152.25
13
A
ARG
28
-85.88
-86.62
13
A
SER
29
-70.39
-164.16
13
A
PHE
30
-70.10
-154.26
13
A
LYS
36
-67.29
-81.31
13
A
PRO
38
-73.47
-154.04
13
A
LYS
39
-52.76
106.16
14
A
ASP
2
-59.11
87.35
14
A
LYS
6
-88.99
39.81
14
A
TRP
7
-150.22
22.35
14
A
ASN
12
-178.64
-56.01
14
A
CYS
17
-53.35
170.57
14
A
CYS
18
-63.43
-123.94
14
A
GLU
19
-46.77
91.81
14
A
ARG
28
-89.04
-71.89
14
A
PHE
30
-69.99
-146.47
14
A
LYS
36
-70.26
-111.31
14
A
LYS
39
-64.30
-73.41
15
A
LYS
6
-95.19
38.51
15
A
TRP
7
-156.86
27.99
15
A
VAL
11
-100.60
71.88
15
A
ASN
12
-176.83
-62.55
15
A
HIS
14
55.70
87.20
15
A
CYS
18
-59.61
-102.60
15
A
GLU
19
-63.30
-157.59
15
A
ARG
28
-79.02
-71.91
15
A
PHE
30
-70.24
-145.19
15
A
LYS
36
-69.23
-102.76
16
A
PRO
5
-53.46
96.18
16
A
LYS
6
-45.76
151.26
16
A
VAL
11
-69.02
69.25
16
A
ASN
12
-177.97
80.13
16
A
HIS
14
42.34
79.43
16
A
CYS
18
-55.71
-105.04
16
A
GLU
19
-57.28
-155.96
16
A
ARG
27
-70.27
-71.52
16
A
ARG
28
-70.88
-76.42
16
A
PHE
30
-57.07
-79.97
16
A
LYS
39
-66.59
75.79
17
A
ASP
2
-59.76
93.93
17
A
CYS
3
-70.42
-169.84
17
A
VAL
11
-67.39
68.68
17
A
ASN
12
-169.95
76.74
17
A
HIS
14
49.04
82.96
17
A
CYS
18
-61.84
-96.38
17
A
GLU
19
-62.56
-154.22
17
A
ARG
27
-70.22
-78.51
17
A
ARG
28
-62.39
-73.39
17
A
PHE
30
-69.07
-81.10
17
A
PRO
38
-69.42
-161.28
18
A
ASP
2
-59.26
105.43
18
A
LYS
6
-55.52
-172.38
18
A
VAL
11
-68.51
72.50
18
A
ASN
12
-176.23
78.23
18
A
HIS
14
47.13
83.93
18
A
CYS
18
-59.22
-100.64
18
A
GLU
19
-70.13
-161.65
18
A
PHE
30
-70.08
-166.74
18
A
LYS
39
-59.59
-74.85
19
A
ASP
2
-66.15
93.36
19
A
CYS
3
-70.29
-84.87
19
A
PRO
5
-59.63
98.37
19
A
TRP
7
64.29
75.68
19
A
ASN
12
-176.90
78.60
19
A
CYS
18
-67.47
-98.10
19
A
GLU
19
-61.33
-155.12
19
A
ARG
28
-81.49
-81.97
19
A
SER
29
-69.83
-179.84
19
A
PHE
30
-69.96
-81.23
20
A
PRO
5
-61.12
93.76
20
A
VAL
11
-68.20
63.05
20
A
ASN
12
174.34
83.11
20
A
ARG
13
70.38
76.28
20
A
CYS
17
-49.91
176.67
20
A
CYS
18
-55.37
-101.79
20
A
ARG
28
-105.30
-67.43
20
A
PHE
30
-70.05
-162.23
20
A
LYS
39
-62.70
86.45
Solution Structure of Psmalmotoxin 1, the First Characterized Specific Blocker of ASIC1a NA+ channel
1
N
N
disulf
2.031
A
CYS
3
A
SG
CYS
3
1_555
A
CYS
18
A
SG
CYS
18
1_555
disulf
2.030
A
CYS
10
A
SG
CYS
10
1_555
A
CYS
23
A
SG
CYS
23
1_555
disulf
2.032
A
CYS
17
A
SG
CYS
17
1_555
A
CYS
33
A
SG
CYS
33
1_555
TOXIN
ICK, TOXIN
TXP1_PSACA
UNP
1
1
P60514
1
40
1LMM
1
40
P60514
A
1
1
40
2
anti-parallel
A
GLU
22
A
GLU
22
A
LYS
25
A
LYS
25
A
GLU
31
A
GLU
31
A
VAL
34
A
VAL
34